Growth meets a regulatory brake.
A tradition-rich pharmaceutical family business faced a critical turning point. Its market products enjoyed an excellent reputation, yet the internal process landscape in GMP manufacturing had grown analogue over decades. While sales operated in a modern way, quality management still rested heavily on paper-based procedures.
The challenge for us as a specialised pharma recruitment firm was the sheer regulatory density. The EU GMP Guide and in particular Annex 11 confronted the company with mounting hurdles. The owner family recognised that without a technological transformation of operations, the future viability of the entire production was at risk.